CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors

Pharmacogenomics and Personalized Medicine

Volumn 6, Issue 1, 2013, Pages 85-91

  Sukasem, Chonlaphat ^a   Tunthong, Ramaimon ^a   Chamnanphon, Montri ^a   Santon, Siwalee ^a   Jantararoungtong, Thawinee ^a   Koomdee, Napatrupron ^a   Prommas, Santirhat ^a   Puangpetch, Apichaya ^a   Vathesatogkit, Prin ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Clopidogrel; CYP2C19 polymorphisms; Non responders; Responders; Thai population

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CLOPIDOGREL; CYTOCHROME P450 2C19; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GENOMIC DNA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG RESPONSE; DYSLIPIDEMIA; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOTE; HUMAN; HYPERTENSION; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PHARMACOGENETICS; PHENOTYPE; PREVALENCE; RETROSPECTIVE STUDY; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; THAILAND; THROMBOCYTE AGGREGATION; THROMBOSIS;

EID: 84882748728     PISSN: None     EISSN: 11787066     Source Type: Journal    
DOI: 10.2147/PGPM.S42332     Document Type: Article

References (38)

1. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 2001;52(4):349-355.
2. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41(12):913-958.
3. Ibeanu GC, Blaisdell J, Ferguson RJ, et al. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther. 1999;290(2):635-640.
4. Miao J, Liu R, Li Z. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(21):2250-2251.
5. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108(7):2244-2247.
6. Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G.A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008;51(20):1925-1934.
7. Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J. 2009;30(8):916-922.
8. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009;373(9660):309-317.
9. Geisler T, Schaeffeler E, Dippon J, et al. CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics. 2008;9(9):1251-1259.
10. Simon T, Verstuyft C, Mary-Krause M, et al; Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363-375.
11. Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci. 2001;22(6):298-305.
12. Sameer AE, Amany GM, Abdela AA, Fadel SA. CYP2C19 genotypes in a population of healthy volunteers and in children with hematological malignancies in Gaza Strip. Can J Clin Pharmacol. 2009;16(1):e156-e162.
13. Freedman JE, Hylek EM. Clopidogrel, genetics, and drug responsiveness. N Engl J Med. 2009;360(4):411-413.
14. Tassaneeyakul W, Mahatthanatrakul W, Niwatananun K, et al. CYP2C19 genetic polymorphism in Thai, Burmese and Karen populations. Drug Metab Pharmacokinet. 2006;21(4):286-290.
15. Koseler A, Ilcol YO, Ulus IH. Frequency of mutated allele CYP2D6*4 in the Turkish population. Pharmacology. 2007;79(4):203-206.
16. Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol. 2008;48(4):475-484.
17. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007;5(12):2429-2436.
18. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation. Blood Coagul Fibrinolysis. 2004;15(1):89-93.
19. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol. 2006;26(8):1895-1900.
20. Fontana P, Dupont A, Gandrille S, et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation. 2003;108(8):989-995.
21. Giusti B, Gori AM, Marcucci R, et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics. 2007;17(12):1057-1064.
22. Taubert D, von Beckerath N, Grimberg G, et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006;80(5): 486-501.
23. Goldstein JA, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics. 1997;7(1):59-64.
24. Herrlin K, Massele AY, Jande M, et al. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clin Pharmacol Ther. 1998;64(4): 391-401.
25. Allabi AC, Gala JL, Desager JP, Heusterspreute M, Horsmans Y. Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br J Clin Pharmacol. 2003;56(6):653-657.
26. Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther. 1996;60(6):661-666.
27. Müller I, Besta F, Schulz C, Massberg S, Schönig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost. 2003;89(5):783-787.
28. He N, Yan FX, Huang SL, et al. CYP2C19 genotype and S-mephenytoin 4′-hydroxylation phenotype in a Chinese Dai population. Eur J Clin Pharmacol. 2002;58(1):15-18.
29. Xiao ZS, Goldstein JA, Xie HG, et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther. 1997;281(1):604-609.
30. Pang YS, Wong LP, Lee TC, Mustafa AM, Mohamed Z, Lang CC. Genetic polymorphism of cytochrome P450 2C19 in healthy Malaysian subjects. Br J Clin Pharmacol. 2004;58(3):332-335.
31. Lamba JK, Dhiman RK, Kohli KK. Genetic polymorphism of the hepatic cytochrome P450 2C19 in north Indian subjects. Clin Pharmacol Ther. 1998;63(4):422-427.
32. Aynacioglu AS, Sachse C, Bozkurt A, et al. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin Pharmacol Ther. 1999;66(2):185-192.
33. Ozawa S, Soyama A, Saeki M, et al. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacokinet. 2004;19(2):83-95.
34. Zand N, Tajik N, Moghaddam AS, Milanian I. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population. Clin Exp Pharmacol Physiol. 2007;34(1-2):102-105.
35. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994;269(22):15419-15422.
36. Nakamura K, Goto F, Ray WA, et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther. 1985;38(4):402-408.
37. Scott SA, Sangkuhl K, Gardner EE, et al; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium (2011) Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-452C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther. 2011;90(2): 328-332.
38. Sim SC, Risinger C, Dahl ML, et al; A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006;79(1):103-113.